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The Opioid Epidemic: A Practice and
Policy Perspective
Introduction
Today I will be talking about the escalating opioid epidemic and
some innovative solutions my colleagues and I at Yale University
and throughout the state of Connecticut, are working on to
mitigate the consequences of this public health crisis. According to
the recent data released from The National Survey on Drug Use and
Health, 20.1 million Americans age 12 and over reported having a
substance use disorder; two million specifically related to opioid
use disorders in 2016. A total of 11.8 million people aged 12 or
older reported a past year opioid misuse. Of these, 8% used heroin
and 92% reported pain reliever misuse only.
Past Year Opioid Misuse
11 .5 Million People
with Past Year
Pain Reliever Misuse
(97.4% of Opioid Misusers)

948,000 People
641 ,000 People with
with Past Year
Past Year Pain Reliever Misuse
Heroin Use
and Heroin Use
(8.0% of Opioid Misusers)
(5.4% of Opioid Misusers)

/
10.9 MIiiion People with
Pain Reliever Misuse Only
(92.0% of Opioid Misusers)

307,000 People
with Heroin Use Only
(2.6% of Opioid Misusers)

11 .8 Million People Aped 12 or Older with Past Year Opioid Misuse

Source: NSDUH, 2016
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Overdose rates and deaths have risen sharply in the past few
years. Data from the Healthcare Costs and Utilization Project
(HCUP) supported from the Agency for Healthcare Research and
Quality (AHRQ) demonstrate that the national rate of emergency
department (ED) visits and inpatient stays for opioid use is going
up every year. Below are data derived from 30 participating states
depicting this escalation, with the State of New York exceeding the
national rates.
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I expect that the numbers will be much higher when new data
comes out.
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The following maps are very telling. They depict the rate of
overdose deaths in the entire United States in 1999 compared to
2015. In 1999, the hot spots, or areas representing 26-28 deaths
per 100,000 individuals, were limited to Appalachian Valley and a
small county in New Mexico.
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Fast forward to 2015, and the signs are more ominous. The number
of overdose deaths increase nationwide with large hot spots in
New England, Ohio and the Appalachian Valley and the southwest.
People are literally dying every day, often in their youth.
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The Faces of Addiction
What do the faces of addiction look like? In 2016, David Armstrong,
a senior enterprise reporter at STAT, owned by the Boston Globe,
published an article entitled “52 weeks, 52 faces: Obituaries
narrate lives lost to the opioid epidemic.” (Armstrong, 2016). To
write this story, Armstrong searched Legacy.com and other sources
to find obituaries of people who died after a struggle with opioid
addiction. One may note that this sample may be biased as the
information is derived from written obituaries, which may say
something about the families’ resources and education. However, it
does reflect that opioid addiction is prevalent in white populations.
These stories are very compelling, and most everyone can identify
or connect with an entry. We have a 27-year-old fitness buff from
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Norwich, Connecticut; a 32-year-old father of two from Cleveland,
Ohio; a 27-year-old, who was one of nine children, from Tolland,
Connecticut; a 52-year-old grandmother from Mansfield, Ohio;
and so on. What this shows you is that these are people within
communities, people that you could know, and people whose lives
were shortened unnecessarily.

Obituaries narrate lives lost to the opioid epidemic
11),DAV ID ARMSTRONG

DavidNff111tongX / DECEMBER 20,

Michael T. Brandon (Feb. 21)

aou;

Alex Thomas Zimmer (J uly 23)

Fitness buff
JVorwich, Connecticut

James R. Gimenez (Sept. 16)
32yearsold
Father of two
Cleveland, Ohio

THE FACES OF ADDICTION
24years old
One of three brothers to die of an overdose

Rockland, Massachusetts

22years old
Mother

Camp Hill, Pen11sylva.nia

Source: Armstrong, 2016

Words Matter
One of the themes that I will repeatedly emphasize is that words
matter. If you remember nothing else today, please remember that
we can all help combat this public health crisis if we use accurate,
less stigmatizing words when talking about addiction. When
individuals feel stigmatized, they are less likely to seek treatment.
They feel ashamed, and this presents an unnecessary barrier to
care.
5
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Instead of calling a person with an addiction an “addict,” we can use
words such as a person with an “opioid use disorder, or addiction.”
Thus, the person is not defined as his or her disease. We do not refer
to individuals with diabetes as that “diabetic over there.” We are
trying very hard to educate journalists and the public to talk about
addiction as a disease. Even though many patients call themselves
addicts, we try as physicians to say, “You may call yourself an addict,
but I’m not going to refer to you like that. You have an opioid use
disorder, and I am going to help you treat that.”
Using accurate words also matters. Often the media is not accurate.
For example, I recently read a post from a New York Times article
that calls a “typical overdose” when a doctor prescribes legally, but
someone other than intended digests the pills. While this was an
important past issue, currently the typical overdose is caused from
the use of heroin or synthetic opioids such as fentanyl. Similarly,
news articles have spoken about the “addicted baby.” This is
impossible, as a baby does not display behaviors such as going
out of their way to seek opioids despite known consequences,
spending all their time seeking opioids and impairing relationships,
etc. Accurately stated, we have babies that suffer from opioid
abstinence syndrome. Recently, my colleagues and I at Yale have
been working with journalists and the news media to make sure
that the information they’re putting out there is accurate and less
stigmatizing.
What is Addiction?
Addiction is a Disease
Addiction is not a moral failing, it is a chronic relapsing disease.
Robert DuPont, who was the first director of the National Institute
on Drug Abuse (NIDA), once told a story that I found very compelling.
He describes a scenario imagining that you are driving a car in a
residential zone at a fast speed and a child runs in front of you.

6

Gail D’Onofrio
You know you need to stop or you’re going to seriously hurt, if
not kill, that child. You try desperately to stop, but you can’t, the
brakes don’t work. You cannot will the breaks to work, just as one
cannot will themselves out of this disease. Similarly, one cannot will
themselves out of diabetes, cancer, or heart disease.
Addiction has potential genetic, environmental, and behavioral
components. There are profound neurobiological changes that
occur when transitioning from opioid use to an opioid use disorder.
The brain is comprised of many areas and neuro circuits that you
see below.

Source: NIDA, 2007

Addiction is thought to, in some way, “hijack” the reward system,
which is mediated through dopamine as a neurotransmitter. Our
reward system is very powerful. It is important for our individual
survival; we need to eat and drink as well to procreate and survive
as a species. When an individual uses heroin they experience an
overwhelming pleasurable response. At some point the reward
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system overpowers the individual’s ability to resist that feeling.
Heroin also affects the prefrontal cortex, which controls our
judgement. Thus, one will seek to use the drug no matter what
the consequences. Why this happens in some individuals and not
others, and why some individuals can use a drug without crossing
over to an addiction is not entirely known.
Chronic Pain vs. Experimental Use (Noble, et al., 2010; Shaheed, et
al., 2016)
It is important to understand the intersection between chronic
pain, opioid use disorder, and experimental use. Both chronic pain
and experimental use can lead to opioid use disorder, but there
are big differences between these groups. Chronic pain affects over
100 million people, or one in three individuals. Twenty-five million
Americans suffer from daily pain, and 40 million from very severe
chronic pain, with costs over $600 billion every year attributable
to treatment costs, lost wages, and productivity. Thus, we need to
find alternative ways to deal with pain, other than opioids. While
individuals may become physically dependent on opioids for pain,
such as someone with end stage cancer, there is a distinction
with developing an addiction. This criteria for addiction entails
continuing to use despite negative consequences, devoting an
enormous amount of time and energy to obtaining the drug, and
its interference with work and personal relationships. In addition,
there are individuals who use these drugs experimentally at parties
etc. Some of these people will use, live through it, and never
develop an addiction. But some individuals will have their reward
system so activated that they will develop an opioid use disorder.
What is an addiction to opioids or an opioid use disorder? The
Diagnostic and Statistical Manual (DSM-5) (American Psychiatric
Association, 2013) for opioid use disorder consists of 11 questions.
Depending on how many questions are positive, one can have a
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diagnosis of a mild, moderate, or severe opioid use disorder. The
most prominent component of the disorder is this first thing on
DSM’s list – taking opioids in really large amounts and for longer
than intended. It is also when you are doing something you cannot
stop, no matter what you try to do, you can’t stop taking it. You could
lose your family, you could lose your job, you could lose everyone
that was significant to you, but it really wouldn’t matter. You’re still
going to use more of it. And you will stop doing other things that
you used to do because you’ve spent all your time thinking about
when you’re going to get your next drug. That is addiction.
What addiction is not. The development of tolerance and the need
for more medication to get the desired effect. For example, with
sickle-cell disease, one will develop a tolerance and need more and
more medication for pain relief through disease progression and
repeated pain crises. In addition, as their body becomes physically
dependent on the medication, they will experience withdrawal
symptoms with abrupt cessation of their medication. This can also
happen to individuals who have progressive cancer. This doesn’t
mean that they have an addiction, because they’re being treated by
physicians who are prescribing the medications as needed.
What Does it Feel Like to Have an Opioid Use Disorder?
Contrary to what one may think, individuals with severe opioid
use disorders are not high all day. They may get some relief from
use, but then they experience large fluctuations from experiencing
cravings and dysphoria, to some relief. While initially they may
experience euphoria, with chronic use the euphoria becomes less
and less and it becomes just a feeling of relief.
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What does it Feel like to have Opioid Use Disorder?
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Days
Source: Dole, Nyswander, and Krock, 1966
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Their life is consumed with not feeling poorly and avoidance of the
horrific withdrawal symptoms. Thus, they are constantly looking for
their next drug. Withdrawal causes irritability, restlessness, nausea,
abdominal pains, and achiness, perhaps the worst flu symptoms
you can imagine.
Fentanyl and Overdoses
Many overdose deaths are now from synthetic opioids such as
fentanyl. The question is, why is so much fentanyl reaching the
market? One answer is that fentanyl is purely synthetic, meaning
it is manufactured in a laboratory. It is relatively easy to make and
it is cheap. Additionally, a lot of fentanyl is brought in from China,
Central America, and South America. So, you can sell fentanyl for
almost the same price as heroin, but since it’s cheaper to make,
you make ten times or twenty times more money. This is scary.
We are seeing so much in circulation and it is so powerful that it
can kill an individual the first time they try it. People may not even
know that what they buy or use is fentanyl. They may think they
10
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are using cocaine or heroin, but actually they are using something
that’s much more powerful. In New Haven, Connecticut we had an
unfortunate experience with 18 overdoses detected in a few hours
that resulted in multiple deaths. These individuals were snorting
a white powder they thought was cocaine, but in reality, it was
fentanyl (Tomassoni et al., 2017). In addition, counterfeit pills are in
circulation and available from the internet that look like an opioid
such as Oxycodone or Percocet, when in fact they are fentanyl. Most
likely the general public will not be able to distinguish between a
real and a counterfeit pill.
The overdose data is always behind, as the CDC reports annually
on the previous year. Unfortunately, we suspect that the 2016 data
will reveal at least 65,000 overdose deaths, and it is estimated to
be around 100,000 in a few years if we continue on the same pace.

U.S. Drug Deaths Climbing
Faster Than Ever

59,000 to 65,000
deaths per year

2016

Source: Katz, 2017
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The Impact of Opioids on Certain Populations
Adolescents are misusing opioids more than they did before.
Adolescent overdose rates have gone up from 1.6 to 3.7 per 100,000
(Curtin et al., 2017). This tells us that that it is important to start
young with prevention.
Women are particularly affected by opioid misuse as well. Women
become dependent more quickly and use it differently. They tend
to take smaller amounts for shorter periods of time, which usually
makes you more dependent. Women are also more sensitive to
cravings.
Older people are also misusing opioids and that, in combination
with chronic diseases, other medications, and co-prescribing,
makes it more difficult to stop overdoses. According to the 2014
NSDUH, opioid use among adults 50 and older has increased from
1% to 2%. One reason may be that while new cancer therapies are
helping many live longer, these individuals are often prescribed
opioids to manage pain. Now, the palliative care team are asking
for help because their patients are living longer than they thought
and are now physically dependent on this medicine.
What Led to this Crisis?
The First Epidemic
We have known about opium since Hippocrates in 400 BC. In 1803
a German pharmacist extracted morphine from opium and called
it Morpheus for the Greek god of dreams. It was right around
this time that we began to have our first epidemic. At the time,
it was considered one of the most useful drugs in the world and
in the physician’s arsenal. However, it apparently tasted very
badly and was associated with many gastrointestinal symptoms.
The development of the hypodermic needle in 1853 allowed for
immediate use in acute pain without these negative side effects.
The advent of the hypodermic needle and intravenous morphine
12
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administration during the Crimean War and the U.S. Civil War,
allowed for the immediate treatment of acute injuries on the
battlefield; but unfortunately, 400-plus soldiers were left with what
was termed “soldier’s disease,” which in reality was an opiate use
disorder.
As the 1800’s continued, addiction became very widespread.
In 1898, Bayer, well known for discovering aspirin, patented
heroin as an improvement over morphine. The use of heroin was
pharmaceutically driven and physicians and pharmacists used it for
everything. Without any scientific knowledge or regulation, heroin
was touted as the best thing for all ailments. People were given it
for everything. Housewives, in particular, developed an addiction
because they were given it often for menstrual cramps, anxiety, or
headaches.
Eventually, the lack of regulation of heroin became evident and in
the early 1900’s. Teddy Roosevelt, with the assistance of a physician
from Ohio, established an opiate commission to begin to develop
regulations. The opiate commission established the Harrison Narcotic
Act, designating morphine a controlled substance. The Food and
Drug Administration (FDA) proclaimed that manufacturers could no
longer add opium and heroin indiscriminately to other substances
and medications. After the Harrison Narcotic Act, regulations were
established regarding indications for the use of opiates such as
heroin and morphine and their distribution. Fortunately, at that
time, there was not a large, lucrative, underground crime network
complicating the expansion of nonprescribed opiates, thus the
epidemic was contained with improved physician knowledge and
the establishment of government regulation.
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The Second Epidemic
The second epidemic was not as big as the first, when opioids were
widespread throughout the U.S., though equally pharmaceutically
driven. In the 1950’s Purdue Pharma was bought by two brothers
who were physicians from New York, Raymond and Mortimer
Sackler. With little data to support the use of OxyContin for pain,
and its supposed lack of addictive potential, they developed and
marketed the drug widely 1996. Pioneers of academic detailing, the
brothers sent pharmaceutical representatives to doctors’ offices
and advertised extensively in an attempt to increase their sales
with over 1 billion reported in 2000.
Another major cause of the second epidemic was a combination of
many soldiers coming back from Vietnam and having widespread
domestic proliferation of heroin on the black market. During this
time, heroin injections became the leading cause of death in New
York City. As a response, methadone clinics were introduced to
treat heroin addiction, which were successful. In addition, in 1971,
we started “the war on drugs”, which we eventually learned did
not work. Consequently, a lot of individuals with addictions were
incarcerated, without treatment or prevention strategies in place.
The Current Epidemic
In the 1990’s we recognized that pain was poorly treated. As
resident physicians, we were told that we did not give out enough
pain medicine, and we were scripted to say to patients in pain “I
have more pain medicine than you have pain.” In 1996 pain became
the fifth vital sign. In addition to the original four primary vital signs
that indicate the status of the body’s vital functions including body
temperature, heart rate, blood pressure, respiratory rate, we were
required to ask about pain.
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We would show patients the pain measurement scale below.

PAIN MEASUREMENT SCALE
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In 2001, the Joint Commission, a non-profit that accredits hospitals
and other U.S. healthcare organizations, set pain management
standards, and we were required to provide pain medicine for
anyone that chose a four or more on this scale. But, as we all know,
pain is very subjective.
We could start with ibuprofen or Tylenol, but if that didn’t work, we
were expected to give them something stronger. To make matters
worse, the Centers for Medicare and Medicaid Services (CMS) linked
our reimbursements with our patient satisfaction. Many emergency
departments throughout the country pay their physicians based
on their patient satisfaction scores. Consequently, many doctors
started overprescribing pain pills to improve their scores.
The combination of all these events, pharmaceutical influence,
pain guidelines, and patient satisfaction scores dictating “so
called quality” and physician reimbursement created a perfect
storm. Today, two out of three people in this country get a pain
pill prescription every single year. Below, you can see the standard
doses of opioids per million. Americans by far consume most of the
opiates in the world and use 99% of the world’s hydrocodone.
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Standard Daily Doses of Opioids per Million Inhabitants
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Opioid Agonist Treatment
An individual with an opioid use disorder (OUD) experiences severe
swings during the day from acute dysphoria or withdrawal and nondysphoric episodes. After use of opioids for long periods they no
longer experience the “high” but fluctuate between these states.
An opioid agonist, such as methadone and buprenorphine, can
stabilize how an individual with OUD feels throughout the day, and
allows one to function at home and work. Opioid agonist treatment
is a very effective. We call it Medication-Assisted Treatment (MAT).
Many believe this is an inaccurate statement and may contribute to
more stigma. For example, we don’t call the treatment for diabetes,
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i.e. insulin, medication assisted treatment. It is the treatment of
diabetes. Thus, a more appropriate term may be medication for
addiction treatment, which would preserve the acronym MAT.
We know that MAT works from multiple studies. Baltimore
Maryland has had a huge problem with heroin overdose deaths.
From 1995-2009, Baltimore expanded the use of buprenorphine
and methadone as part of their opioid agonist treatment, and as
you can see in the graph below, the number of deaths markedly
decreased with the expansion of methadone treatment programs
and the ability of physicians to prescribe buprenorphine in 2002.
Heroin OD Deaths during Expansion of Methadone &
Buprenorphine in Baltimore, 1995-2009
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We have also seen examples of this happening in Sweden and
France. Recently, in the British Medical Journal, a major analysis of
multiple studies demonstrated that use of MAT prevents overdoses,
compared to no MAT (Sordo, 2017).
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One question frequently asked regarding Opioid Agonist Treatment
is whether patients need counseling in addition to medication.
A large Cochrane review that was recently published included a
systematic review of 34 randomized clinical trials with 3,777 patients
receiving buprenorphine or methadone with basic versus additional
structured counseling (Mattick et al., 2014). They concluded “the
present evidence suggests that adding psychosocial support does
not change the effectiveness of retention in treatment and opioid
use during treatment.” It seems intuitive that, what I like to call “life
coaching,” can be added because we do need these individuals to
be an active part of our society, to work and be viable members of
the community. Thus, education, obtaining GEDs, or making sure
individuals have adequate housing is all necessary for maintaining
recovery. And we know that often individuals with opioid use
disorder have co-existing mental illness, and these conditions need
to be adequately treated. But, an essential aspect of treatment is
medication or MAT, specifically opioid agonist treatment.
Advantages of Opioid Agonist Treatment
Opioid Agonist Treatment reduces withdrawal symptoms, cravings
and illicit drug use. It also reduces transmission of hepatitis, HIV,
and complications from IV drug use such as skin infections and
abscesses. It reduces overdose, death, and other risky behavior such
as high risk sexual behavior without adequate protection. MAT also
reduces legal consequences and crime. Finally, it allows individuals
to sustain relationships and find meaningful employment. MAT
also makes good economic sense. Every dollar spent on addiction
treatment yields a return of $4.00-$7.00 in reduced drug-related
activities such as crime, criminal justice costs, and theft. The total
savings to healthcare exceed costs by a ratio of 12:1, from data
reported in 2012.
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Without adequate treatment, more people are going to die. 2015
was the first year in recent history that life expectancy in the U.S.
fell, primarily in the white male population due to the surge in
fatal opioid overdose deaths (Rudd et al., 2016). MAT is endorsed
by almost every agency you can think of - the World Health
Organization, the National Institute of Health (NIH), the National
Governor’s Association, the Surgeon General, the Office of National
Drug Control Policy, and the Substance Abuse and Mental Health
Services Administration (SAMHSA).
Limited Access to Opioid Agonist Treatment
In a special report in The New England Journal of Medicine, Dr. Nora
Volkow, director of the National Institute on Drug Abuse (NIDA)
and Dr. Francis Collins, director of National Institutes of Health,
say “These medications coupled with psychosocial support are the
current standard of care for reducing illicit opioid use, relapse risk,
and overdoses, while improving social function. However, limited
access to providers and programs can create barriers to treatment.”
(Volkow and Collins, 2017). Even with all this knowledge and
evidence, only a third of drug treatment centers use MAT (SAMHSA
TED, 2013 & Knudsen, Abraham, & Roman, 2011). This means
that a lot of the time, patients come out of abstinence based
rehabilitation programs and they end up dying. We know that
release from any controlled abstinence environment, be it a drug
program or incarceration, is a major risk factor for overdose and
death. This results from the individual becoming less tolerant, and
with relapse they overdose.
A study published last year in The Journal of the American Medical
Association examined the medications provided before and after
an opioid overdose event from 2008-2013 in the Pennsylvania
Medicaid system. Unfortunately, very few of these people were
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ever prescribed medication treatment for opioid use disorder after
they overdosed. In addition, there was little reduction in the opioids
they were prescribed! (Frazier, Winfred, et al., 2017).
Medication Patterns Before and After Heroin or Opioid Overdose Events, 2008-2013
Characteristics
Any prescription
opioid use
Prescription opioid
duration > 90d
Any medication-assisted
treatment
Buprenorphine
Methadone
Naltrexone

Heroin Overdose n=2068)
Before overdose
After overdose
%
%

Prescription Opioid Overdose(n=3945)
Before overdose
After overdose
%
%

43.2

39.7

66.1

59.6

10.5

9.0

32.4

28.3

29.4

33.0

13.5

15.1

19.2
10.4
2.4

20.3
12.6
3.0

5.4
8.2
0.4

6.7
8.3
0.8

Source: Frazier, Winfred, et al., 2017

So, moving forward, we have clear evidence that we need to fund
treatment and promote behavioral health parity so that people have
access to this treatment. The Urban Institute recently published a
study titled, “Rapid Growth in Medicaid Spending on Medications
to Treat Opioid Use Disorders and Overdose,” which looked at the
rapid growth in Medicaid spending on medications to treat opioid
use disorder and prevent overdose (Clemans-Cope et al., 2017).
The next graph depicts the medications used to treat opioid use
disorder, and the money spent on these medications over the years.
The spending is increasing and this is a good thing.
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Medicaid Spending on Buprenorphine, Naltrexone, and Naloxone
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The following graph looks at Medicaid spending for states with and
without Medicaid expansion. If you were in an expanded state, the
money spent is increasing and people are accessing medications.
Unfortunately, if you were in a non-expansion or a late expansion
state, money was not being allocated for effective treatment. The
bottom line is, we need to make sure that everyone who needs
these medications for treatment has access to them.
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Medicaid Spending on Buprenorphine, Naltrexone, and Naloxone
Prescriptions for OUD, by State
Millions of dollars
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Source: Clemans-Cope et al., 2017

Connecticut Opioid Response (CORE)
The Connecticut Opioid REsponse (CORE) was created as part of
Governor Dannel Malloy’s strategic initiative to reduce overdose
deaths. A group of Yale University Professors led by Dr. David
Fiellin, including myself, Dr. William Becker, and Dr. Robert Heimer
partnered with many agencies and organizations within the state
to develop this plan. Our goal to reduce deaths included six specific
strategies, including increasing access to MAT, reducing OD risk,
safe prescribing, increasing access to Naloxone, data sharing, and
reducing stigma.
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Access
to MAT

Reducing
the Stigma

Reduce
OD Risk

Reduce OD
Deaths

Safe
Prescribing

_,,_

Data
Sharing

Increase
Access to
Naloxone

Reduce the Risk of Overdose
We needed to educate the medical community and the public
regarding those at highest risk for overdose. This includes those
with a prior non-fatal opioid overdose; leaving a controlled settings
such as residential treatments, detoxification or incarceration who
have lowered opioid tolerance; those prescribed doses of opioid
analgesic greater than 90 milligram morphine equivalents (MME)
per day; those who are co-prescribing or co-using opioids and
benzodiazepines or injecting opioids; those with exposure to high
potency opioids (fentanyl, W-18), low levels of physical tolerance
(new initiates); and those with sleep disordered breathing such as
obstructive sleep apnea.
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Safe Prescribing
All states in the U.S., except for Missouri, have prescription
monitoring programs (PMP). Most states require that a physician
reviews the program if writing an opioid prescription for more
than 72 hours to assess if other providers are prescribing opioids
or other narcotics. This alone is not a panacea, as individuals who
are buying illicit drugs are obviously not in the system. However,
the PMP is associated with less deaths. There were an estimated
600 fewer overdoses nationwide in 2016 with the implementation
of this program, so there is value to accessing the system (Patrick,
Fry, et al., 2016).
The CDC also published guidelines for doctors who prescribe
opioids. Two recent articles highlight the importance of prescribing
short courses of opioids when necessary. A recent article in
Morbidity and Mortality Weekly reported the characteristics of
initial prescription episodes and the likelihood of long-term opioid
use in a sample of patients (2006-2015) derived from the IMS
Lifelink+ database (commercially insured population). The authors
found that prescribing three days or less of opioids, often sufficient
for most acute pain, was associated with a relatively low long-term
rate of opioid use (6%). This rate of long-term use significantly
increased to 13.5% for persons whose first episode of use was for >
8 days and to 29.9% when the first episode of use was for > 31 days
(Dowell, Haegerich & Chou, 2016).
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One- And 3-Year Probabilities of Continued Opioid Use Among
Opioid-Naïve Patients,
By Number of Days’ Supply* of the First Opioid Prescription —
United States, 2006–2015
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Another paper published in the New England Journal in 2017
investigated whether overuse of opioids may be driven in part
by physician prescribing. Researchers performed a retrospective
analysis involving Medicare patients who had an index ED visit from
2008-2011. Emergency physicians within a hospital were categorized
as being high-intensity or low-intensity opioid prescribing according
to quartiles of prescribing rates within the same hospital. They then
compared rates of long-term opioid use (defined as 6 months of
days supplied) in the 12 months post ED visited among patients
treated by high-intensity or low-intensity prescribers. They found
a wide variation in rates of opioid prescribing existed among MDs
practicing in the same ED. Long-term opioid use at 12 months was
25

Lourie Lecture Policy Brief
significantly higher among patients treated by the high-intensity
prescribers (adjusted odds ratio, 1.3; 95% CI 1.23 to 1.37; p<0.001)
(Barnett, Olenski, et al., 2017).
So, we have pretty good evidence that we need to prescribe less
and more judiciously. We have to recognize that we may be part of
the problem.
Increase Access to Naloxone (Narcan)
Naloxone is an opioid agonist and its use is a life-saving intervention.
The medication can be administered intravenously, in a nasal
spray (ADAPT), or is available in an atomizer form, which must be
assembled and is more challenging in an emergency. We know that
having naloxone available to individuals with an opioid use disorder
and their family or community can be life- saving. Personally, I
believe this should be available in any public place, for example in
an automatic defibrillator, along with an EpiPen. We need them in
airplanes, churches, coffee houses, any place that people gather.
There are Good Samaritan overdose immunity laws in many states.
These laws protect a person if you are using with someone and
that person overdoses. With these laws in place, you can call 911,
administer naloxone, and you will have immunity from arrest if first
responders or police find you with drug paraphernalia.
Data Sharing
Data sharing is essential if a community is to have timely information
regarding surveillance of use, overdose, treatment availability,
etc. States such as Massachusetts and Maryland (Baltimore) have
assembled comprehensive strategic plans, and they have shared
data with insights. However, it continues to be a challenge within
and among states. In Connecticut, Governor Malloy signed into law
a legislation package that said we could data share between state
agencies regarding opioid misuse and opioid overdose deaths.
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This law allows us to obtain data so we can map out hot spots of
overdose and use, and determine whether these individuals were
or are currently in treatment, have visited an ED, etc.
Reduce the Stigma
Another major initiative that the CORE team is focused on is reducing
the stigma of having an opioid disorder, which brings us back to
where we started, that words have power. This is something that
we just need to keep talking about. We hosted a media roundtable
at Yale University and we talked about laypeople’s views and
increasing community understanding of opioid use disorder and
treatment. We want to let people know that language is powerful,
especially when talking about substance use disorders. So, we’d like
you to avoid certain terms and replace them with other language
instead. Stigma may place an unnecessary barrier between need
and treatment and we are working hard to reduce its impact.
When Discussing Addictions...
Avoid These Terms:

Use These Instead:

Addict, user, drug abuser,
junkie

Person/Patient with
opioid use disorder or
opioid addiction

Addicted baby

Baby born with neonatal
abstinence syndrome

Opioid abuse or opioid
dependence

Opioid use disorder

Problem

Disease

Habit

Drug addiction

Clean or dirty urine test

Relapse

Negative or positive urine drug
test
Opioid agonist treatment
Medication for Addiction
Treatment
Return to use/ Setback

Treatment failure

Treatment attempt

Being clean

Being in remission or recovery

Opioid substitution or
replacement therapy

27

Lourie Lecture Policy Brief
Language is important, so we should be saying “a person with
an addiction” or “a person with an opiate use disorder” instead
of “an addict” or “a junkie.” Instead of “opiate abuse” or “opiate
dependence,” we’d like to talk more about “opioid use disorder.”
We avoid the term “opioid substitution” or “replacement therapy,”
because it is not substituting one drug for another. It’s a medication,
whether it’s buprenorphine or methadone, and it is given in
prescribed doses under a doctor’s supervision. Using this language
can be hard, even for me, but it is essential if we are going to change
the climate and avoid contributing to the stigma that surrounds this
disease.
What are Solutions to the Opioid Epidemic?
One thing we know about this epidemic is that arrests and use of
the judicial system does not work. We’ve already tried this and our
jails are full of individuals with substance use disorders. The war on
drugs only led to more and more people being incarcerated. The
Court Appointed Special Advocates (CASA) reported data last year
that 85% of the U.S. prison population either has an addiction or
their lives were affected by substance use.
Get People into Treatment
Despite how prevalent opioid addiction is, only one in five people
get treatment. That is abhorrent. So, what are some things that I
can do as an emergency physician? I can work on increasing access
to treatment. Why the emergency department? We are the front
door of the hospital, and we are where the patients are. A famous
bank robber was once asked, “Why do you rob banks?” and his
answer was, “I rob banks because that’s where the money is.” The
emergency department is where many receive their care, so why not
use the ED visit as an opportunity to help? Sometimes people come
in seeking treatment directly, or we see them for complications
of injection use, such as skin infections, or they present with an
overdose, or we identify their disease through screening. In any
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case, we have the opportunity to intervene and engage them in
treatment.
So, my colleagues and
Intrinsic Activity
I had this great idea.
What if we could initiate
Full Agonist
(Methadone)
treatment while these
patients were in the ED?
Many of these are young
patients without other
chronic diseases and
Partial Agonist
(Buprenorphine)
primary care physicians.
We thought, maybe we
could initiate opioid
Antagonist
(Naloxone)
agonist treatment with
Log Dose
buprenorphine and help
Source: The National Alliance of
make this direct linkage
Advocates for Buprenorphine Treatment
to ongoing maintenance
therapy. We shifted the
paradigm and started treating opioid disorder like any other disease
or emergency in the case of overdose - and we could do that with
buprenorphine, a medication that physicians have been capable of
using since 2002.
Buprenorphine is a partial agonist, which means it has a ceiling
effect, and after a certain dose its effect levels off. It has a very
high affinitive to the receptors in the brain. Unlike buprenorphine,
methadone is a pure agonist. The effect continues as the dose rises
and it can therefore be lethal. Naloxone is an antagonist, not to
be confused with naltrexone, which you may hear about regarding
treatment. Naloxone is not treatment, but the antidote to overdose,
precipitating withdrawal. So, buprenorphine is an ideal medication
to initiate in the ED. It is often combined with naloxone to prevent
diversion. When taken sublingually it is absorbed and effective.
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Unfortunately, in order to prescribe buprenorphine (often known
as Suboxone) a physician must obtain an X waiver from the Drug
Enforcement Administration (DEA). This process includes four hours
of online training and an additional four hours of in person training,
and this is often a barrier for physician prescribing. You may find this
very ironic since any physician can prescribe thousands of opioid
pills such as OxyContin and oxycodone, but we need an eight hour
course to treat opioid use disorders. Fortunately, there is a 72-hour
rule [Title 21, Code of Federal Regulations, Part 1306.07(b)] that
allows physicians to administer (but not prescribe) narcotic drugs
for the purpose of relieving acute withdrawal symptoms, while
arranging for the patient’s referral for treatment. According to this
rule, no more than one day of medication may be administered
or given to a patient at one time. The patient must return to the
ED each day, for no more than 72 hours, and this period cannot
be renewed or extended. This can work well, but one limitation is
that the emergency physician has arranged someplace to send the
patient for ongoing care.
My colleagues and I conducted a study to compare the efficacy of
three intervention methods for opioid dependent ED patients. 329
patients were enrolled in this study from April 2009-June 2013. Our
question was “How should we treat them?” One intervention was
just referring them. These referrals were more than your typical
referral – a list of local providers and programs were provided based
on the patient’s insurance and preference. The second arm involved
a brief psychosocial intervention, namely the Brief Negotiation
Interview or BNI, where our goal was to motivate them to accept
treatment. The brief intervention was followed by a facilitated
referral. We contacted the program, arranged transportation if
necessary, and in some cases even received clearance through
insurance companies to get people into treatment. The third arm
of this study, included the BNI plus ED-initiated buprenorphine,
either administered in the ED or given as a take home dose if the
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patient was not in sufficient withdrawal to initiate treatment at the
time of the ED visit. A sufficient supply was given to take home for
at most 72 hours when they received an appointment for follow
up in our primary care center, where treatment was continued for
10 weeks. Our primary outcome was treatment engagement at 30
days. We found that almost 80% in the ED-initiated buprenorphine
group were in a formal treatment program at 30 days compared
with brief intervention or referral (see below).
Engaged in Treatment at 30-Days
100%
90%

.,>

P<0.001

VI

C

.,
.,
.,

80%

0

M

C:

70%

60%

E

~

·=0

50%
40%

C:

'i:

30%

0

C.

!?

20%

Q.

10%

II.

0%

Referral

Brief Intervention

Buprenorphine

Source: D’Onofrio, O’Connor, et al., 2015

We also found that in our buprenorphine group, there were few
with inpatient treatment compared to the others, which is of course
very cost-effective.
We also performed a cost-effective analysis (Busch, 2017) and
found out that willingness to pay for every dollar, whether it was
for treatment engagement or whether it was for one day free of
opiates, for every dollar, buprenorphine proved to be more cost
effective. Thus, our mantra that “we need more chairs, not beds”
for the treatment of opioid use disorder. You really don’t need
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inpatient stays for this. You need the medication. We concluded that
with ED-initiated buprenorphine treatment and follow-up in our
primary care, we improved engagement in treatment; decreased
people’s illicit use; and reduced inpatient services; all while being
cost-effective.
How Do We Apply this to the Real World and Move Forward?
(Sharfstein, 2017)
Here is an example of a real patient that was pulled out of a vehicle
unresponsive. Her oxygen was very low. She was given naloxone
and after she woke up she said she had just switched over from
prescription drugs to IV heroin. Why should this case be treated
differently than other emergencies? We resuscitate people all the
time, and we do it in a very specific way. Patients who are about
to die receive urgent propriety in ED care, for example, patients
who have had a stroke or myocardial infarctions (MI). For MI and
stroke, we know we have a certain amount of time to get them
to definitive treatment, and we have created specific quality
measures, such as time from door to EKG, EKG to the catherization
laboratory, and time to opening the culprit lesion. In stroke, we
have door to needle (medication administration) time. We don’t
hand out a pamphlet and say, “You’re having a big heart attack, but
it’s Friday, so I’m going to give you this pamphlet and you can go
out and find a cardiologist and laboratory to open up that coronary
artery for you. But with your insurance I don’t think you’re going to
find somebody over the weekend. See you later, and good luck.” In
the past, that’s exactly what we have done for patients who present
with an overdose or signs and symptoms of opioid use disorder
that we know are at high risk for overdose. They came in, they may
have even been dead at the time, we revived them, we observed
them for a while, and we get them out of the ED in a couple hours.
What we’re trying to present as best practice now, is to observe
these patients and start treatment when appropriate. Let’s start to
engage them in this conversation. Even if they didn’t come in for an
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overdose, but we know they’re going to die from a variety of other
issues, let’s still try to engage them and give them a facilitated
referral. Then, let’s engage them in harm reduction strategies such
as overdose education and naloxone distribution. If we did all of
this, we could really save lives. We now have several emergency
physicians leading this charge throughout the country, not only in
Connecticut. We have Dr. Sullivan, who has started his own clinic
in Syracuse, New York, Dr. Herring in Oakland, California, and two
ED physicians in Camden, New Jersey working at Cooper Hospital.
These are the real heroes. They saw a problem and stepped up to
the plate, against all odds, to do something about it.

Emergent
Care

SAVE A LIFE

.. ..
Observation
& Initiate TX

Facilitated
Referral

Naloxone
Prescription

SAVE A LIFE

Conclusion
The opioid crisis is escalating. Lives are being wasted every day.
We have the opportunity to change this, adapting evidence
based therapies and developing state wide strategies that focus
on increasing access to MAT, identifying high risk individuals, safe
prescribing, offering harm reduction strategies, sharing data and
decreasing stigma. Most of all, we hope to change three keys about
addiction: the way we think about it, the way we talk about it, and
the way we treat people that have an addiction.
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